Consensus is for FY23 revenue $1.05B. FY23 revenue view represents 24%-26% growth over 2022 revenue of $847.1M. The company added, “We continue to expect growth in our global vascular business to be slightly above this range and growth in our global neuro business to be below this range for the FY23.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PEN:
- Penumbra, Inc. Reports Second Quarter 2023 Financial Results
- PEN Upcoming Earnings Report: What to Expect?
- Penumbra price target raised to $370 from $350 at Truist
- Penumbra initiated with an Outperform at Baird
- Penumbra price target raised to $351 from $328 at BTIG
Questions or Comments about the article? Write to editor@tipranks.com